How Will Menlo Therapeutics (MNLO) Stock React to The Latest Coverage By Cantor Fitzgerald?

September 8, 2018 - By Pearl Odom

How Cantor Fitzgerald Currently Rates Menlo Therapeutics (MNLO)

Analysts at Cantor Fitzgerald has begun coverage on Menlo Therapeutics (MNLO) with “Overweight” rating. This was published in an analyst note on 7 September.

Menlo Therapeutics Inc. (NASDAQ:MNLO) Ratings Coverage

Among 4 analysts covering Menlo Therapeutics Inc. – Common Stock (MNLO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Menlo Therapeutics Inc. – Common Stock has $25 highest and $1100 lowest target. $18.67’s average target is 140.90% above currents $7.75 stock price. Menlo Therapeutics Inc. – Common Stock had 5 analyst reports since April 9, 2018 according to SRatingsIntel. Piper Jaffray maintained Menlo Therapeutics Inc. (NASDAQ:MNLO) on Monday, April 9 with “Buy” rating. Jefferies downgraded the shares of MNLO in report on Monday, April 9 to “Hold” rating. Guggenheim maintained the shares of MNLO in report on Tuesday, April 24 with “Buy” rating.

The stock increased 1.57% or $0.12 during the last trading session, reaching $7.75. About 222,468 shares traded or 34.99% up from the average. Menlo Therapeutics Inc. (MNLO) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Menlo Therapeutics Inc. (NASDAQ:MNLO) to report earnings on November, 7. After $-0.36 actual earnings per share reported by Menlo Therapeutics Inc. for the previous quarter, Wall Street now forecasts 133.33 % negative EPS growth.

Menlo Therapeutics Inc., a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has market cap of $178.08 million. The firm has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It currently has negative earnings. It is also developing products that are in Phase II clinical trials in pruritus associated with psoriasis and atopic dermatitis, and refractory chronic cough.

More important recent Menlo Therapeutics Inc. (NASDAQ:MNLO) news were published by: Streetinsider.com which released: “Cantor Fitzgerald Starts Menlo Therapeutics (MNLO) at Overweight” on September 06, 2018, also Benzinga.com published article titled: “Benzinga’s Top Upgrades, Downgrades For September 7, 2018”, Nasdaq.com published: “Consolidated Research: 2018 Summary Expectations for SpartanNash, Encana, Hilltop, Pacira Pharmaceuticals …” on August 23, 2018. More interesting news about Menlo Therapeutics Inc. (NASDAQ:MNLO) was released by: Streetinsider.com and their article: “After-Hours Stock Movers 09/06: (OKTA) (FNSR) (FIVE) Higher; (EGAN) (MNLO) (HOME) Lower (more…)” with publication date: September 06, 2018.

Menlo Therapeutics Inc. (NASDAQ:MNLO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.